Autoantibody production in Anti-TNF-α-Treated patients

被引：19

作者：

Alessandri, Cristiano ^{[1
]}

Scrivo, Rossana ^{[1
]}

Spinelli, Francesca Romana ^{[1
]}

Ceccarelli, Fulvia ^{[1
]}

Magrini, Leonardo ^{[1
]}

Priori, Roberta ^{[1
]}

Valesini, Guido ^{[1
]}

机构：

[1] Univ Roma La Sapienza, Dipartimento Clin & Terapia Med, Rheumatol Sect, Policlin Umberto I, I-00161 Rome, Italy

来源：

AUTOIMMUNITY, PT B: NOVEL APPLICATIONS OF BASIC RESEARCH | 2007年 / 1110卷

关键词：

autoantibodies; human antichimeric antibodies (HACA); infliximab; rheumatic inflammatory disorders;

D O I：

10.1196/annals.1423.034

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Targeting tumor necrosis factor alpha (TNF-alpha) has offered an additional therapeutic strategy against several rheumatic inflammatory disorders. The current use of TNF-alpha inhibitors allows physicians who manage these diseases and patients themselves to testify to an extraordinary efficacy, even though caution for possible adverse events must be maintained. Among these, the occurrence of autoimmune phenomena, encompassing new autoantibody formation and triggering of clinical manifestations, continues to be noted in published reports. Here, we review the current knowledge regarding the autoimmune phenomena linked to anti-TNF-alpha therapy in patients with rheumatic inflammatory disorders.

引用

收藏

页码：319 / 329

页数：11

相关论文

共 66 条

[1] Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFα therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement [J].

Alessandri, C ;

Bombardieri, M ;

Papa, N ;

Cinquini, M ;

Magrini, L ;

Tincani, A ;

Valesini, G .

ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (10) :1218-1221

[2]

Allanore Y, 2004, CLIN EXP RHEUMATOL, V22, P756

[3] Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study [J].

Atzeni, F ;

Sarzi-Puttini, P ;

Dell'Acqua, D ;

de Portu, S ;

Cecchini, G ;

Cruini, C ;

Carrabba, M ;

Meroni, PL .

ARTHRITIS RESEARCH & THERAPY, 2006, 8 (01)

[4] Demonstration of specific antibodies against infliximab induced during treatment of a patient with ankylosing spondylitis [J].

Aybay, C ;

Ozel, S ;

Aybay, C .

RHEUMATOLOGY INTERNATIONAL, 2006, 26 (05) :473-480

[5] Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease [J].

Baert, F ;

Noman, M ;

Vermeire, S ;

Van Assche, G ;

D'Haens, G ;

Carbonez, A ;

Rutgeerts, P .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07) :601-608

[6] Immunogenicity, efficacy and adverse events of adalimumab in RA patients [J].

Bender, Niko K. ;

Heilig, Christoph E. ;

Droell, Benjamin ;

Wohlgemuth, Jessica ;

Armbruster, Franz-Paul ;

Heilig, Bernhard .

RHEUMATOLOGY INTERNATIONAL, 2007, 27 (03) :269-274

[7] Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab [J].

Bendtzen, Klaus ;

Geborek, Pierre ;

Svenson, Morten ;

Larsson, Lotta ;

Kapetanovic, Meliha C. ;

Saxne, Tore .

ARTHRITIS AND RHEUMATISM, 2006, 54 (12) :3782-3789

[8]

Bensouda-Grimaldi L, 2007, J RHEUMATOL, V34, P239

[9] THE CUTANEOUS LYMPHOCYTE ANTIGEN IS A SKIN LYMPHOCYTE HOMING RECEPTOR FOR THE VASCULAR LECTIN ENDOTHELIAL CELL-LEUKOCYTE ADHESION MOLECULE-1 [J].

BERG, EL ;

YOSHINO, T ;

ROTT, LS ;

ROBINSON, MK ;

WARNOCK, RA ;

KISHIMOTO, TK ;

PICKER, LJ ;

BUTCHER, EC .

JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 174 (06) :1461-1466

[10] Distal lower extremity paresthesia and foot drop developing during adalimumab therapy [J].

Berthelot, CN ;

George, SJ ;

Hsu, S .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 53 (05) :S260-S262

← 1 2 3 4 5 6 7 →